Board Member
Niagen Bioscience, Inc. (NAGE)Equibles does not estimate personal net worth.
Get an email with a short summary when Niagen Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAGE alertsRobert Fried is recorded as Board Member at Niagen Bioscience, Inc. (NAGE) since January 1, 2015 and CEO at Niagen Bioscience, Inc. (NAGE). The newest filing on record that lists Robert Fried as CEO and Board Member at Niagen Bioscience, Inc. (NAGE) is dated April 29, 2026. Niagen Bioscience, Inc. reported in an 8-K filed June 27, 2025 that Robert Fried was appointed director, effective June 24, 2025. The proxy statement of Niagen Bioscience, Inc. reports total compensation of $8,381,900 for Robert Fried in fiscal 2025, including a base salary of $645,962. Disclosed compensation is on record for 7 fiscal years. Robert Fried has spoken on 3 earnings calls across 1 company, most recently for Niagen Bioscience, Inc. on May 8, 2024. Niagen Bioscience, Inc. is classified in the Packaged Foods industry within the Consumer Defensive sector. Other leadership on record at Niagen Bioscience, Inc. includes Frank Jaksch (Chairman and Board Member), James Lee (CFO and Chief Accounting Officer), Ozan Pamir (CFO and Chief Accounting Officer) and 7 others.
“The following directors were elected to serve until the Company's 2026 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director's death, resignation or removal.”
“Thank you, Ben, and good afternoon, everyone, and thank you for joining us on today's investor call. I'm proud to announce that we delivered a solid start to 2024, delivering $22.2 million in revenue and positive adjusted EBITDA of $0.7 million.”
“For the third quarter, we delivered a significant improvement in adjusted EBITDA or cash EBITDA, which is a $1.2 million loss. And we remain on track to deliver positive EBITDA in the fourth quarter of this year.”
“And thank you for joining our first quarter 2021 investor call. This has been a very exciting time strategically for ChromaDex. In the past few months we added $25 million to the balance sheet.”
2015-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Proxy statement
Start not stated–2020-04-21
Last confirmed by a filing; no departure on record
Packaged Foods · Consumer Defensive
CEO, Board Member
2015-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $645,962 | $8,381,900 |
| 2024 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $500,000 | $1,212,131 |
| 2023 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $500,000 | $1,160,206 |
| 2022 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $500,000 | $1,158,850 |
| 2021 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $500,000 | $1,103,160 |
| 2020 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $519,231 | $1,126,685 |
| 2019 | Niagen Bioscience, Inc. (NAGE) | Chief Executive Officer | $486,537 | $1,711,894 |
